Table 5 Costs of drug, administration and management of adverse events per patient (euros). Final results of the economic analysis

From: Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

 

PLD

Topotecan

Difference

Total cost: drug+administration

8647.70

8519.94

127.76

 Drug cost

7785.43

4256.66

 

 Administration cost

862.27

4263.29

 

Total cost adverse events

967.02

3304.75

−2337.73

 Anaemia

334.25

1687.19

 

 Thrombocytopenia

4.51

337.51

 

 Neutropenia

45.32

859.82

 

 Sepsis

48.49

209.61

 

 Fever

15.53

36.41

 

 Stomatitis/pharyngitis

163.94

23.00

 

 Nausea/vomiting

69.48

115.84

 

 Diarrhoea

210.01

35.37

 

 PPE

75.49

0.00

 

Total cost

9614.72

11 824.69

−2209.97

  1. PLD=pegylated liposomal doxorubicin hydrochloride; PPE=palmar-plantar erythrodysesthesia.
Back to article page